Novartis India has acquired the 'Minipress' and 'Minipres' trademarks and related intellectual property from Pfizer for Rs 1,250 crore. The acquired brand, focused on hypertension and BPH treatment, generated Rs 228.6 crore in revenue as of July 2026. This strategic acquisition expands the company’s product portfolio in high-demand therapeutic areas.
Novartis India Acquires Minipress Trademarks For Rs 1,250 Crore
Aggregate consideration: Rs 1,250.001 crore.
Target brand revenue (IQVIA MAT July 2026): Rs 228.6 crore.
Reader Takeaway: Acquisition strengthens hypertension portfolio with established brand, though brand growth trails category average of 9% CAGR.
What just happened
Novartis India Limited has officially acquired the trademarks 'Minipress' and 'Minipres' along with related intellectual property from Pfizer Inc. USA and Pfizer Products Inc. USA. The asset purchase agreement and assignment deeds were executed and closed simultaneously on September 07, 2026. The transaction is not a related party deal.
Why this matters
The deal represents a major capital deployment to consolidate Novartis India’s footprint in the hypertension and benign prostatic hyperplasia (BPH) therapy markets. By integrating 'Minipress XL', a recognized brand in these segments, the company secures an existing revenue stream of Rs 228.6 crore.
The backstory
The acquisition targets products containing prazosin. Market data indicates the brand has seen a 6.3% CAGR over the last four years. While this reflects consistent demand, the relevant product category has outpaced this at 9% CAGR, highlighting potential for operational improvements under the new management.
Risks to watch
Investors should monitor the company's ability to boost the brand’s current growth rate, which has historically trailed the broader category. Execution risk remains in successfully integrating the brand into the existing distribution and marketing infrastructure without margin dilution.
Context metrics
- Acquisition cost: Rs 1,250.001 crore
- Minipress XL annual revenue: Rs 228.6 crore
- Brand CAGR (4 years): 6.3%
- Category CAGR (4 years): 9%
What to track next
Watch for upcoming quarterly results to see the impact of this asset on the company’s top-line revenue and the effectiveness of their strategy to align the brand's growth with industry category standards.